DBV Technologies to Showcase Innovations at Major Conference
DBV Technologies, a clinical-stage biopharmaceutical company focused on food allergies, is gearing up for its participation in the upcoming Guggenheim 2nd Annual Healthcare Innovation Conference. The event is set to underline the significant advancements in the field of allergy treatment, particularly for food allergies, a condition affecting millions globally.
Leadership Engagement at the Conference
Daniel Tassé, the Chief Executive Officer of DBV Technologies, will lead a fireside chat during the conference. This interactive session will take place at 2:00 p.m. ET, designed to provide insights into the company’s innovative approaches and ongoing research in allergy treatment.
Accessing the Event
Individuals interested in following the discussion can access a live webcast of the fireside chat. The link will be posted for viewing and will remain available on the company’s Investor website section for up to 90 days after the event, allowing a broader audience to engage with the content.
Focus on Advanced Allergy Treatments
DBV Technologies specializes in the development of treatment options for food allergies and other immunologic disorders. Through its proprietary VIASKIN® patch technology, the company aims to change how severe allergic reactions are treated. The innovative system utilizes epicutaneous immunotherapy (EPIT) to re-educate the immune system, which is particularly crucial for individuals, especially children, suffering from food allergies.
Innovative Technology and Clinical Trials
The VIASKIN® patch introduces micrograms of biologically active compounds through intact skin, thereby reducing the sensitivity of the immune system to specific allergens. This technique marks a turning point in non-invasive treatment methods, with ongoing clinical trials focusing on peanut allergies in toddlers and children aged up to seven years. These trials aim not only to alleviate symptoms but to transform the lives of young allergy sufferers by offering a pathway to greater safety.
Commitment to Public Health and Research
DBV Technologies is steadfast in its mission to enhance the quality of life for individuals with food allergies. With the growing prevalence of these conditions, their dedicated research and development efforts are more critical than ever. The company’s focus on innovative solutions underscores the importance of advancing healthcare to tackle the pressing need for effective treatment options.
Company Structure and Operations
DBV Technologies is headquartered in Châtillon, France, and has expanded its operations into North America, signaling its growth and commitment to addressing global health challenges. The company’s ordinary shares are listed on segment B of Euronext Paris under the ticker DBV, and their American Depositary Shares (ADSs) are traded on the Nasdaq Capital Market as DBVT. This dual listing supports broader investment opportunities and showcases the company’s increasing importance within the healthcare sector.
Continuing the Conversation: Contact Information
For those seeking more information regarding their initiatives and innovations, DBV Technologies offers multiple channels for engagement. The Investor Relations contacts are always available to address inquiries and provide further insights.
Engaging with DBV Technologies
As DBV Technologies actively communicates through channels like their website and professional networking sites, it's encouraging stakeholders to follow their developments. Engaging with the company via their social media platforms provides an additional layer of transparency regarding their ongoing projects and innovations.
Frequently Asked Questions
What is DBV Technologies known for?
DBV Technologies is recognized for developing innovative treatments for food allergies, especially using their VIASKIN® patch technology.
Who is presenting at the upcoming conference?
Daniel Tassé, CEO of DBV Technologies, will present during the Guggenheim 2nd Annual Healthcare Innovation Conference.
How can I access the conference?
Details for accessing the conference webcast will be available on DBV Technologies' Investor website.
What types of clinical trials is DBV Technologies conducting?
They are conducting clinical trials focused on peanut allergies among children, using their unique epicutaneous immunotherapy approach.
Where is DBV Technologies headquartered?
DBV Technologies is located in Châtillon, France, with additional operations in North America.
